Detalhe da pesquisa
1.
Human monoclonal antibody F61 nasal spray effectively protected high-risk populations from SARS-CoV-2 variants during the COVID-19 pandemic from late 2022 to early 2023 in China.
Emerg Microbes Infect
; 13(1): 2284297, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37970736
2.
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Virol Sin
; 37(2): 238-247, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35527227
3.
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages.
Cell Discov
; 8(1): 87, 2022 Sep 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36075908
4.
Chemiluminescence Immunoassay Based Serological Immunoassays for Detection of SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Vaccinated Population.
Viruses
; 13(8)2021 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34452373
5.
Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants.
Virol Sin
; 36(5): 934-947, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34224110
6.
Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients.
Sci Rep
; 11(1): 6811, 2021 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-33762651
7.
Hemorrhagic Fever with Renal Syndrome - Liaoning Province, China, 1999-2018.
China CDC Wkly
; 2(20): 350-354, 2020 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34594659